Article
Regeneron's Eylea could return to growth after nod to high-dose version- analysts
Rating:
0.0
Views:
73
Likes:
1
Library:
1
A quicker-than-expected U.S. approval for Regeneron Pharmaceuticals' high-dose eye disease drug, Eylea, should help return the blockbuster treatment back to growth in the next few years, Wall Street analysts said.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value